Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

van Doremalen N. et al, (2021), Nature

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Lambe T. et al, (2021)

Solar inactivated Salmonella Typhimurium induces an immune response in BALB/c mice

Ssemakalu CC. et al, (2021), Heliyon, 7, e05903 - e05903

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2020), Nature Medicine

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2020), Nature Medicine

MAIT cell activation augments adenovirus vector vaccine immunogenicity

PROVINE N. et al, (2020), Science

Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule

Rollier CS. et al, (2020), Scientific Reports, 10

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2020), The Lancet

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen N. et al, (2020), Nature, 586, 578 - 582

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Graham SP. et al, (2020)

A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector

Sebastian S. et al, (2020), Vaccines, 8, 241 - 241

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.

Graham SP. et al, (2020), NPJ vaccines, 5

Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria

Halbroth BR. et al, (2019), Infection and Immunity, 88

An effective multi-pathogen vaccine targeting filoviruses and an arenavirus

Flaxman A. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 1690 - 1691

NOVEL METHODS TO DETERMINE LIVER-STAGE MALARIA VACCINE CORRELATES OF PROTECTION: KINETICS, DEEP IMMUNE PHENOTYPING AND TRANSCRIPTOMICS

Noe A. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 415 - 415

PRIME-TARGET IMMUNISATION WITH LIVER-STAGE MALARIA VACCINES: A FIRST-IN-HUMAN CHALLENGE TRIAL

Datoo M. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 415 - 415

Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice

Brod F. et al, (2018), Frontiers in Immunology, 9

Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses

Halbroth BR. et al, (2018), Scientific Reports, 8

Load More

Include forthcoming?